Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Cancer Prevention Research (Philadelphia, Pa.)|October 29, 2020
Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular CancerMartha D Gay, Anita Safronenka, Hong Cao, et al.
Discovery Medicine|May 1, 2012
Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancerDiana M Tacelosky, Amy E Creecy, Sriram S Shanmugavelandy, et al.
Pharmaceutics|March 26, 2022
Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic ImpairmentChristine C Hsu, Sunil Bansal, Hong Cao, et al.
International Journal of Molecular Sciences|February 25, 2023
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular CarcinomaNarayan Shivapurkar, Martha D Gay, Aiwu Ruth He, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 22, 2018
Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptorSandeep Nadella, Julian Burks, Abdulhameed Al-Sabban, et al.
International Journal of Molecular Sciences|January 8, 2023
Target-Specific Nanoparticle Polyplex Down-Regulates Mutant Kras to Prevent Pancreatic Carcinogenesis and Halt Tumor ProgressionJill P Smith, Wenqiang Chen, Narayan Shivapurkar, et al.
Cellular and Molecular Gastroenterology and Hepatology|June 22, 2018
Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic CancerJulian Burks, Sandeep Nadella, Abdullah Mahmud, et al.
Cancers|October 13, 2021
Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor MicroenvironmentZoe X Malchiodi, Hong Cao, Martha D Gay, et al.
Pancreas|July 25, 2014
Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in miceJill P Smith, Timothy K Cooper, Christopher O McGovern, et al.
Clinical Pharmacology and Therapeutics|September 10, 2022
Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic SteatohepatitisAtoosa Rabiee, Martha D Gay, Narayan Shivapurkar, et al.
Pageof 7